Diana Beyer

446 total citations
10 papers, 354 citations indexed

About

Diana Beyer is a scholar working on Oncology, Immunology and Allergy and Immunology. According to data from OpenAlex, Diana Beyer has authored 10 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Immunology and Allergy and 3 papers in Immunology. Recurrent topics in Diana Beyer's work include Cancer Immunotherapy and Biomarkers (4 papers), Cell Adhesion Molecules Research (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). Diana Beyer is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Cell Adhesion Molecules Research (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). Diana Beyer collaborates with scholars based in Germany, Austria and Italy. Diana Beyer's co-authors include Matthias Baumann, Dirk Eulberg, Jan Menne, F Saudek, Zsuzsanna Valkusz, Andrzej Więcek, Hermann Haller, Niels Halama, G. Wolff and Michael C. Meyer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Diana Beyer

10 papers receiving 345 citations

Peers

Diana Beyer
Wanjun Shen China
Paula Fernández‐Calotti Argentina
Karim Bennaceur United Kingdom
I. Kubota Japan
A. Hitz Germany
Ylenia Bevelacqua Italy
Woo Young Sun South Korea
Jennyfer Bultinck Belgium
Wanjun Shen China
Diana Beyer
Citations per year, relative to Diana Beyer Diana Beyer (= 1×) peers Wanjun Shen

Countries citing papers authored by Diana Beyer

Since Specialization
Citations

This map shows the geographic impact of Diana Beyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana Beyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana Beyer more than expected).

Fields of papers citing papers by Diana Beyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana Beyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana Beyer. The network helps show where Diana Beyer may publish in the future.

Co-authorship network of co-authors of Diana Beyer

This figure shows the co-authorship network connecting the top 25 collaborators of Diana Beyer. A scholar is included among the top collaborators of Diana Beyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana Beyer. Diana Beyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Suarez‐Carmona, Meggy, Anja Williams, Nicolas Hohmann, et al.. (2021). Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects. Journal for ImmunoTherapy of Cancer. 9(10). e002505–e002505. 57 indexed citations
2.
3.
Steurer, Michael, Marco Montillo, Lydia Scarfò, et al.. (2019). Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. 104(10). 2053–2060. 69 indexed citations
4.
Halama, Niels, et al.. (2019). Experience with CXCL12 inhibitor NOX-A12 plus pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer.. Journal of Clinical Oncology. 37(15_suppl). e14143–e14143. 8 indexed citations
5.
6.
Menne, Jan, Dirk Eulberg, Diana Beyer, et al.. (2016). C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. Nephrology Dialysis Transplantation. 32(2). 307–315. 154 indexed citations
7.
Mayr, Florian, Christa Firbas, Judith Leitner, et al.. (2008). EFFECTS OF THE PAN-SELECTIN ANTAGONIST BIMOSIAMOSE (TBC1269) IN EXPERIMENTAL HUMAN ENDOTOXEMIA. Shock. 29(4). 475–482. 10 indexed citations
8.
Meyer, Michael C., et al.. (2007). The pharmacokinetics of subcutaneously injected bimosiamose disodium in healthy male volunteers. Biopharmaceutics & Drug Disposition. 28(9). 475–484. 4 indexed citations
9.
Kranich, Remo, Daniel Bock, Diana Beyer, et al.. (2007). Rational Design of Novel, Potent Small Molecule Pan-Selectin Antagonists. Journal of Medicinal Chemistry. 50(6). 1101–1115. 35 indexed citations
10.
Meyer, Michael C., Kai Michael Beeh, Jutta Beier, et al.. (2006). Tolerability and pharmacokinetics of inhaled bimosiamose disodium in healthy males. British Journal of Clinical Pharmacology. 63(4). 451–458. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wanjun Shen Breakdown of academic impact, for papers by Paula Fernández‐Calotti Breakdown of academic impact, for papers by Karim Bennaceur Breakdown of academic impact, for papers by I. Kubota Breakdown of academic impact, for papers by A. Hitz Breakdown of academic impact, for papers by Ylenia Bevelacqua Breakdown of academic impact, for papers by Woo Young Sun Breakdown of academic impact, for papers by Jennyfer Bultinck
Rankless by CCL
2026